Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Bristol Myers Squibb CofiledCriticalFive Prime Therapeutics Inc
Priority to CL2022002288ApriorityCriticalpatent/CL2022002288A1/en
Publication of CL2022002288A1publicationCriticalpatent/CL2022002288A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente solicitud se relaciona con anticuerpos que se unen específicamente al supresor de activación de células T que contiene inmunoglobulina con dominio V (VISTA) a pH ácido y su uso en el tratamiento del cáncer, En algunas realizaciones, los anticuerpos se unen específicamente a VISTA humano a pH ácido, pero no se unen significativamente a VISTA humano a pH neutro o fisiológico.The present application relates to antibodies that specifically bind to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and its use in the treatment of cancer. In some embodiments, the antibodies specifically bind to VISTA human at acidic pH, but do not significantly bind VISTA human at neutral or physiological pH.